Efmitermant alfa

依米特安α

Report date: 2022/10/14 20:00:43

Base Information

Drug NameEfmitermant alfa

Drug Alias NameEfmitermant alfa - Acceleron PharmaACE-083

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein

Mechanisms of ActionTransforming growth factor beta inhibitors

TargetsTransforming growth factor beta

Therapy Area/IndicationsCharcot-Marie-Tooth DiseaseMuscular Dystrophy, Facioscapulohumeral

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanadaUnited StatesSpain

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

China Registration ClassN/A

Active CompaniesN/A

Active IndicationsN/A

Inactive IndicationsCharcot-Marie-Tooth DiseaseMuscular Dystrophy, Facioscapulohumeral

ATC CodeN/A